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ASBMT POLICY STATEMENT2009 Research PrioritiesThe American Society for Blood and Marrow
Transplantation has reviewed recent advances and
problems in hematopoietic cell transplantation
(HCT), and has identified priorities in several areas
of basic and clinical research:
 Stem Cell Biology (cell manipulation, sources of
stem cells, inducible pluripotent stem cells, cancer
stem cells)
 Tumor Relapse (prevention of and therapy for post-
transplant relapse, immunotherapy with T cells and
dendritic cells)
 Graft-versus-Host Disease (separation of GVHD
and graft-versus-tumor effects, immune reconstitu-
tion and GVHD, markers predicting GVHD, role
of regulatory T cells)
 Applying New Technology to HCT (genomics,
proteomics, imaging, markers of immunologic
recovery, pharmacogenomics)
 Expanded Indications for HCT (solid tumors,
regenerative medicine, autoimmune diseases, re-
sponse to bioterrorism and radiation accidents)
 Survivorship (long-term complications, longevity,
quality of life)
 Transplants in Older Patients (biology of aging,
indications, outcomes and quality of life)
 Improving Current Use of HCT (graft sources,
conditioning intensity, cost-effectiveness)
These research areas are closely interrelated and of
growing importance as a greater number and higher
risk patients are being transplanted. Each area has an
interface between basic science and clinical practice.
Research in each of these areas can have direct and
immediate clinical benefits.STEM CELL BIOLOGY
Multiple sources of stem cells are now available
for transplantation, including bone marrow, mobi-
lized peripheral blood stem cells and umbilical cord
blood, as well as cells induced to provide particular
biological functions. The development of these mul-
tiple sources was initially for the purpose of expand-
ing the donor pool and facilitating access, but it now
is clear that these cell populations have considerable
differences that can be therapeutically exploited. A
better understanding of stem cell biology is needed
to optimize the therapeutic potential of these several
cell sources. That understanding is essential tosuccessful action against cancer stem cells, with dif-
fering repopulation kinetics, repair capacities and
treatment resistance. More investigations are needed
to better define the potential of inducible pluripotent
stem cells and problems that may be associated with
their use.TUMOR RELAPSE
Relapse remains of paramount concern after autol-
ogous HCT for the treatment of hematologic malig-
nancies. We need to understand the mechanisms by
which cancer cells can resist cytotoxic therapies in
autologous HSCT. Use of immune therapies, mono-
clonal antibodies, molecular targeted agents and che-
motherapeutics – alone or in combination – should
be explored in the context of HCT. This may also
help in applying autologous HCT to a wider spectrum
of malignancies.
Disease recurrence remains a major problem after
allogeneic HCT in which cytotoxic therapy is com-
bined with immunotherapy provided by donor cells.
A better understanding of the mechanisms by which
cancer cells resist cytotoxic therapy might lead to
more effective immunotherapies, be they cellular, hu-
moral or vaccination, or a combination of these. These
efforts also should include strategies for patients with
minimal residual disease after transplantation who
are at a high risk of relapse but who may also be
more responsive to immunotherapy.
Studies have shown the effective use of adoptive T
cell transfer after reduced-intensity conditioning in
patients with melanoma. However, adoptive therapy
with allogeneic cells also is associated with the risk of
GVHD. Therefore, techniques that modify autolo-
gous cells so they can be used for tumor antigen-
specific immunotherapy might improve efficacy and
decrease toxicity. Studies on cell trafficking of immune
effector cells may also provide important information
on the role of ‘‘homing’’ receptors and how those could
be used to design more effective therapy.GRAFT-VERSUS-HOST DISEASE
GVHD is still the most frequent complication
after HCT. While the use of reduced-intensity condi-
tioning regimens appears to lower the incidence – and
possibly severity – of acute GVHD, there has been1489
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derstanding of the pathobiology of chronic GVHD
and must find new ways to target it clinically. The
identification of early biomarkers and prognostic indi-
cators could be helpful in distinguishing patient popu-
lations whomight benefit from different preemptive or
therapeutic strategies. Rather than broad immunosup-
pression, targeted approaches and possibly selective
immunostimulation should be explored. It is likely
that this will lead to more individualized management
that considers the underlying disease, conditioning
used for transplantation, prior therapy and patient
age, among other factors.
The role of regulatory T cells, shown to be of cen-
tral importance for tolerance in animal models, de-
serves clinical exploration. Natural killer (NK) cells
are another effector arm in need of better characteriza-
tion, both as anti-tumor effectors and as immunodula-
tors. Similarly, NK/T cells and suppressive dendritic
cell subsets require investigation of their immuno-
modulatory effects. Understanding pathways that can
distinguish GVHD from the graft -versus -tumor
effect and the roles of the various immune cell popula-
tions in these processes continue to be of central
importance for applying HCT in cancer therapies.APPLYING NEW TECHNOLOGY TO HCT
The advent of proteomic and genomics has in-
creased the need to validate potential clinical markers.
Such markers have important implications for patient
selection, prognosis and treatment. Application of
new imaging techniques will not only allow assessment
of clinical efficacy and cellular therapy trafficking, but
also advance our basic understanding of disease pro-
cesses. Using proteomics to determine correlative
markers for GVHD progression and to identify
high-risk patients is of considerable importance.
Enzyme polymorphisms are likely relevant for drug
metabolism and tissue repair, and a better understand-
ing of these relationships could help tailor condition-
ing regimens and GVHD prophylaxis. Another
critical area is development of immune monitoring
parameters that reflect immune competence and re-
covery, particularly with the increasing use of HCT
in older patients.EXPANDED INDICATIONS FOR HCT
HCT may have applications in solid organ
transplantation by inducing immune tolerance. Stud-
ies of the application of HCT to solid tumors are
a priority.
HCT also may be useful in other therapies includ-
ing, but not limited to, regenerative medicine (heart
disease and others), autoimmunity and restorationof hematopoiesis and immunity in the advent of
bioterrorism attack or mass radiation accident. Pre-
clinical and clinical studies of immune reconstitution,
tolerance, efficacy and long-term effects will aid in
understanding the applicability of HCT in these
conditions and situations.SURVIVORSHIP
Some former patients have now been followed for
three and four decades after transplantation – cured of
their disease, but not necessarily without long-term
complications. Patients are dealing with problems
such as chronic GVHD, immune deficiency, endocri-
nologic failure, bone loss and secondary malignancies.
Recent data suggest that life expectancy in patients
afterHCT is shortened by about 30 percent, compared
with age -matched controls. Thus, there is a high
priority for investigations of risk factors for late com-
plications, development of relevant preclinical models,
design of interventional strategies to prevent compli-
cations and development of better means of assessing
quality of life in long-term survivors.TRANSPLANTS IN OLDER PATIENTS
Older patients, who are an increasingly dominant
population with respect to cancer and other diseases,
represent unique challenges in biologic understand-
ing and extrapolation of preclinical findings and clin-
ical studies. Toxicities of cytoreductive therapies are
heightened in the older patient. Poor immune func-
tion in the aged leads to increased susceptibility to
opportunistic infections and relapse from the cancer.
The science of aging needs to be applied to HCT.
There are basic questions about the effects of age
on hematopoiesis, immune function and response to
insult and stress. These need to be coupled with clin-
ical studies on the effects of age on recovery, out-
comes and quality of life and general questions
about ‘‘gain’’ versus ‘‘loss’’ that may be associated
with HCT.IMPROVING CURRENT USE OF HCT
We need to define the optimal stem cell sources
(cord blood, peripheral blood stem cells, bonemarrow,
and ex vivo expanded stem cell populations) and condi-
tioning intensity as they relate to the treatment of
specific diseases.
Finally, it must be acknowledged that HCT can
be resource intensive and expensive. There is
a need for studies of the cost-effectiveness of HCT
compared to other therapies for achieving desired
outcomes.
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The ASBMT Board of Directors and Executive
Committee wish to thank the members of the Task
Force on Research Priorities that helped with the de-
velopment of this policy statement: H. Joachim
Deeg, MD (chair), John F. DiPersio, MD, PhD, James
W. Young, MD, Richard T. Maziarz, MD, Claude
Perreault, MD, and David A. Margolis, MD, Robert
H. Collins MD. The Board of Directors also wishes
to acknowledge the recommendation and encourage-
ment of the ASBMT Corporate Council to develop
these research priorities.
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